ClinicalTrials.gg

Program

JNJ-64264681

Its studies are mostly in Lymphoma, Non-Hodgkin · Leukemia, Myeloid, Acute, led by Johnson & Johnson.

Furthest: phase 1, since Jul 24, 20184 company-led studies, 1 open or runningNext primary completion: Jan 19, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson41 open or runningphase 1since Jul 24, 2018Jul 24, 2018Jan 19, 2028phase 1 · NCT06788509

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 24, 2018First study: phase 1 study in HealthyFirst studyNCT03607513 · 105 enrolled · Belgium
  2. Dec 23, 2019Phase 1 study in Lymphoma, Non-HodgkinNCT04210219 · 85 enrolled · United States, Georgia, Moldova and more
  3. Dec 1, 2020Phase 1 study in Lymphoma, Non-HodgkinNCT04657224 · 75 enrolled · United States, Australia, Belgium and more
  4. Jan 16, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT06788509 · 120 planned · Australia, Belgium, Denmark and more

Ahead

  1. Jan 19, 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT06788509

TargetBeta

BTK →read by rule
“An orally bioavailable and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06788509Leukemia, Myeloid, Acute · Australia, Belgium, Denmark and more1By invitationJan 19, 2028120
NCT04657224Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more1CompletedJan 16, 202575
NCT04210219Lymphoma, Non-Hodgkin · United States, Georgia, Moldova and more1CompletedMay 28, 202585
NCT03607513Healthy · Belgium1CompletedAug 9, 2019105

How it is read

Names in the registry

  • “JNJ-64264681”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.